BiotechTube

LY2216684

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depressive Disorder, Major

Conditions

Depressive Disorder, Major

Trial Timeline

Oct 1, 2010 → Apr 1, 2011

NCT ID
NCT01241435

About LY2216684

LY2216684 is a phase 1 stage product being developed by Eli Lilly for Depressive Disorder, Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01241435. Target conditions include Depressive Disorder, Major.

What happened to similar drugs?

20 of 20 similar drugs in Depressive Disorder, Major were approved

Approved (20) Terminated (0) Active (0)
✅Mirtazapine TabletsSun PharmaceuticalApproved
✅DuloxetineEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅DuloxetineEli LillyApproved
✅Duloxetine hydrochlorideEli LillyApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01389765Phase 1Completed
NCT01241435Phase 1Completed

Competing Products

20 competing products in Depressive Disorder, Major

See all competitors
ProductCompanyStageHype Score
duloxetineEli LillyPre-clinical
26
Duloxetine HydrochlorideEli LillyPre-clinical
26
LY2216684Eli LillyPhase 1
29
DuloxetineEli LillyPhase 3
40
LY2216684 + DigoxinEli LillyPhase 1
29
Duloxetine + ParoxetineEli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
35
FK949EAstellas PharmaPhase 1
29
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
35
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
Mirtazapine TabletsSun PharmaceuticalApproved
43
Duloxetine HydrochlorideShionogiPhase 3
32
Duloxetine Hydrochloride + PlaceboShionogiPhase 3
40
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Pramipexole ER + EscitalopramCiplaPhase 2
42
LY2216684 + SertralineEli LillyPhase 1
29